**Supplementary Table 4. Correlation between circRNA and patients’ laboratory measurements**

|  |  |
| --- | --- |
| Variables | circRNA value  |
| **r** | ***p*-value** |
| TLC (×109/L) | .092 | 0.631 |
| Hb (g/dL) | .012 | 0.948 |
| Platelets (×10³/µL) | -.042 | 0.826 |
| Creatinine (mg/dL) | -.338 | 0.067 |
| Total bilirubin (mg/dL) | .622 | 0.000\*\* |
| Direct bilirubin (mg/dL) | .473 | 0.008\*\* |
| AST (IU/L) | .463 | 0.010\* |
| ALT (IU/L) | .082 | 0.655 |
| INR | .315 | 0.090 |
| Albumin (g/dL) | -.058 | 0.762 |
| AFP (ng/mL) | .225 | 0.232 |
| ALBI score | .360 | 0.051 |
| CRP (mg/L) | -.095 | 0.617 |
| NLR | .774 | 0.000\*\* |
| PLR | .727 | 0.000\*\* |
| AST/ALT ratio | .330 | 0.075 |
| FIB 4 | .051 | 0.790 |
| APRI | -.080 | 0.675 |
| NFS | .349 | 0.058 |
| MELD | .151 | 0.427 |
| MELD NA | .337 | 0.069 |

\*Statistically significant at *p* < 0.05. \*\*Highly statistically significant at *p* < 0.01. AFP, alpha-feto protein; ALBI, albumin-bilirubin score; ALT, Alanine Aminotransferase; APRI, AST to Platelet Ratio Index; AST, aspartate aminotransferase; CRP, C. reactive protein; FIB-4, Fibrosis-4 ; INR, international normalized ratio; MELD NA, Model for End-Stage Liver Disease score-Na*;* MELD, Model for End-Stage Liver Disease score; NFS, Nonalcoholic Fatty Liver Disease Fibrosis Score; NLR, Neutrophil-to-Lymphocyte Ratio; PLR, platelet-to-lymphocyte ratio; TLC, total leucocytic count.